A Dose Finding Study of Debio 4228 in Participants With Locally Advanced/Metastatic Prostate Cancer - Trial NCT06395753
Access comprehensive clinical trial information for NCT06395753 through Pure Global AI's free database. This Phase 2 trial is sponsored by Debiopharm International SA and is currently Not yet recruiting. The study focuses on Prostate Cancer. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Debiopharm International SA
Timeline & Enrollment
Phase 2
Jun 01, 2024
Apr 01, 2026
Primary Outcome
Maximum Plasma Concentration (Cmax) of Debio 4228,Area Under the Concentration-time Curve of Debio 4228 Over 12 weeks (AUC84d),Plasma Concentration of Debio 4228 at Week 12 (C84d),Serum Concentration of Testosterone
Summary
The primary purpose of this study is to determine the pharmacokinetics (PK) and
 pharmacodynamics (PD) of Debio 4228.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06395753
Non-Device Trial